As we entered 2023, China’s pharmaceutical economy embarked on a new phase of high-quality development marked by a rebound in growth.

Recently, through the precise recommendation of GuChuan United, a traditional Chinese medicine enterprise successfully signed an agreement to establish operations at the Guangdong Medical Valley Nansha Industrial Park.

As an investment and incubation platform under the Zhongchuang Group specializing in the biopharmaceutical and medical device industries, Guangdong Medical Valley has become a globally influential innovation hub for the pharmaceutical sector.

Since the start of the partnership, Guchuan United has focused on the cutting edge of the industry and has facilitated the establishment of several high-quality enterprises in Guangdong Medical Valley, covering fields such as ophthalmic surgical robots, human stem cell technology, traditional Chinese herbal slices, biotechnology, and artificial intelligence.

By continuously facilitating the establishment of cutting-edge pharmaceutical companies, Guchuan United’s effectiveness in attracting investment is steadily improving.

The "City of Venture Capital" Thrives Endlessly

On February 18, 2023, the inaugural ceremony for the Guangzhou Industrial Investment Fund of Funds, the Guangzhou Innovation Investment Fund of Funds, and the Guangzhou Industrial Development Research Institute was held.

After two years of planning, the Guangzhou Industrial Investment Fund (with a total scale of 150 billion yuan) and the Guangzhou Innovation Investment Fund (with a total scale of 50 billion yuan) have finally been established, both based in Nansha District, where they will focus on supporting a range of strategic emerging industries.

With this move, Guangzhou is taking a giant stride toward becoming a "City of Venture Capital."

The rise of state-owned capital, represented by government-guided funds, will significantly invigorate the venture capital sector and drive rapid growth in market scale.

In fact, as a major strategic platform rooted in the Greater Bay Area, collaborating with Hong Kong and Macao, and facing the world, Nansha has always maintained a vibrant atmosphere for science and technology innovation.

Take Guangdong Medical Valley, for example. Rooted in Nansha and having grown steadily, it has become a rising star in the Greater Bay Area’s biopharmaceutical industry.

Guangdong Medical Valley has built a resource-rich industry exchange and service platform, regularly hosting various events such as the Guangdong Medical Valley Open Day, the “Guangdong Medical Valley Cup” Healthcare and Wellness Startup Competition, the Guangdong International Medical Industry Expo, and the selection of the Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area.

The Guangdong Medical Valley Open Day—a project roadshow and exchange platform hosted by Guangdong Medical Valley and co-organized by CUVENT—has been held for 194 consecutive sessions. Emerging industry investment institutions active in Guangzhou’s venture capital circle all come here to exchange ideas on core technologies with entrepreneurs and seek investment opportunities.

This first-class venture capital ecosystem is a key reason why many cutting-edge pharmaceutical companies have chosen to establish operations in Guangzhou Medical Valley.

▲ On February 1, 2023, the 188th Guangdong Medical Valley Open Day was held in Guangzhou, featuring impressive pitch presentations on projects such as peptide-conjugated drugs, cellular immunotherapy products, smart ophthalmic devices, and stem cell-based medical treatments.

Pharmaceutical companies are both technology-intensive and capital-intensive; without sufficient technology and funding, it is difficult for startups to succeed.

Guangdong Medical Valley collaborates closely with renowned investment institutions such as IDG, Sequoia Capital, Fosun Pharma, Songhe Capital, Dachen Venture Capital, and Northern Light Venture Capital. It also partners with multiple banks and securities firms to provide enterprises with a variety of flexible and convenient financing services, including equity financing, bond financing, and credit guarantee services.

An ophthalmic medical project that moved into the Guangdong Medical Valley Nansha Industrial Park in 2020 through the recommendation of Gu-Chuan United has now grown into a star enterprise within the park.

From the perspective of clinical ophthalmology, the company’s surgical robots have demonstrated outstanding performance in complex retinal surgeries, such as subretinal injections using ultra-fine needles, effectively reducing iatrogenic injuries and shortening recovery times.

Pragmatic Guangdong-based capital, astute venture capital firms, and state-owned capital with industrial advantages will accelerate a wave of industrial innovation in Guangzhou.

Positioned as an investment and incubation platform, Guangdong Medical Valley is also set to enter a new phase of accelerated development.

Xie Jiasheng, Executive President of Guangdong Medical Valley, stated that the park hosts numerous innovative projects, most of which are small-scale but high-growth high-tech enterprises—a profile that aligns with the investment focus of the 50-billion-yuan innovation investment fund.

Currently, Guangdong Medical Valley has attracted over 300 biopharmaceutical enterprises, covering specialized fields such as biopharmaceuticals, high-end medical devices, gene editing, immunotherapy, and stem cells, and has gathered a number of innovative projects with global influence.

Partnering with Guchuan United, Guangdong Medical Valley Sets Sail for a New Blue Ocean in Biopharmaceuticals

The vibrancy of the capital markets in the biopharmaceutical sector has also spurred new site selection demands among enterprises.

Unlike conventional manufacturing, biopharmaceutical companies, due to the unique nature of their equipment and processes, place greater emphasis on the alignment of building specifications with actual needs when selecting a location.

However, current national design codes only specify minimum permissible limits for parameters such as load-bearing capacity. Industrial facilities built solely to meet these minimum standards struggle to precisely align with companies’ actual needs.

This is precisely one of the challenges biopharmaceutical companies frequently face when selecting a location.

With 14 years of deep expertise in investment promotion, Guchuan United leverages its battle-tested investment promotion team and cutting-edge digital tools to resolve the information asymmetry challenges inherent in industrial park recruitment and corporate site selection.

On one hand, having focused on the Greater Bay Area for eight years, we have become professional site selection advisors for enterprises, drawing on our deep understanding of emerging industries and comprehensive knowledge of high-quality facilities.

On the other hand, through channels such as our investment promotion network and XuanNai.com, we present the location factors most critical to enterprises in the most intuitive way to companies seeking new sites.

For example, at the Guangdong Medical Valley Nansha Industrial Park, the floor load capacity on the 6th floor and above is 500 kg/m², far exceeding the 200–300 kg/m² typical of conventional office buildings. This allows its upper-level spaces to accommodate not only office needs but also R&D and production requirements.

Additionally, the park is equipped with production and R&D facilities—including GMP-compliant factories, shared laboratories, and bonded warehouses—as well as lifestyle amenities such as employee cafeterias, star-rated apartments, and fitness centers. This comprehensive range of facilities meets enterprises’ needs from production to daily living, complemented by a wealth of industry networking events and recreational activities—a level of service many industrial parks cannot match.

This precise alignment between the park’s investment promotion requirements and enterprises’ site selection needs has fostered a mutually beneficial partnership between the park and its tenants (see below for information on selected projects).

Since the start of our collaboration, GuChuan United has focused on the cutting edge of the industry and has successfully facilitated the establishment of several high-quality enterprises in Guangdong Medical Valley, covering fields such as ophthalmic surgical robots, human stem cell technology, traditional Chinese herbal decoctions, biotechnology, and artificial intelligence.

As Guangdong Medical Valley sparks a new wave of growth in the biopharmaceutical industry, Nansha has also embarked on a new chapter of transformation and upgrading.

"Pharmaceutical Powerhouse" Awaits Nansha’s Answer

The pivotal role of the biopharmaceutical industry in driving the development of the Guangdong-Hong Kong-Macao Greater Bay Area is becoming increasingly evident. According to statistics from professional institutions, the market size of the Greater Bay Area’s biopharmaceutical industry is projected to reach nearly 200 billion yuan in 2023, demonstrating immense growth potential.

Currently, a number of innovative pharmaceutical companies are successively establishing production and R&D bases in Nansha. The Nansha biopharmaceutical cluster is gradually taking shape and gaining momentum, presenting an increasingly refined value chain.

So, in 2023, which new growth sectors will revitalize China’s pharmaceutical economy?

In response, Lin Jianning, Party Secretary of the Southern Pharmaceutical Economics Research Institute under the National Medical Products Administration, identified four key directions.

First, continued growth in the "fourth channel."

In the wake of the pandemic, consumer habits regarding medication purchases have shifted. Although online payments for medical insurance are not yet available, there is a strong trend toward online medication purchases, and the integration of brick-and-mortar stores with online platforms is the prevailing direction.

Second is the rapid development of the integration of pharmaceuticals and medical devices.

Global pharmaceutical giants have all entered the digital therapeutics sector and are conducting related business in over 22 sub-sectors.

Third, the CDMO sector maintains strong market momentum.

As competition intensifies, the simple contract manufacturing provided by traditional CMOs can no longer meet pharmaceutical companies’ needs for cost reduction and efficiency improvements; the professional division of labor in drug innovation will become even more specialized.

Fourth is the revolution in drug R&D efficiency driven by artificial intelligence (AI).

The explosive popularity of ChatGPT has further drawn capital attention to AI+pharmaceutical applications.

Domestically, AI technology is primarily applied in the drug R&D phase. According to international statistical standards, AI can predict the success of clinical trials with an accuracy rate of approximately 87%, potentially shortening drug discovery time by 40% and reducing clinical trial duration by 50%.

While a recovery in China’s pharmaceutical economy is expected in 2023, trends toward differentiation and transformation are becoming increasingly pronounced; innovation remains the only path to realizing the dream of becoming a pharmaceutical powerhouse.

Technological innovation serves as a safeguard for the development of the biopharmaceutical industry, and Nansha’s technological advancement will continue unabated. In the future, more biopharmaceutical companies will emerge from Nansha to take on the world, adding momentum to Nansha’s high-quality development.

Let us look forward to Nansha’s answers.